Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts

BioCentury This Week

English - April 19, 2022 01:00 - 20 minutes - 14 MB - ★★★★★ - 11 ratings
Science biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Ep. 111 - Seeking Green Shoots Amid Biotech’s Gloom

Next Episode: Ep. 113 - Nkarta’s Breakthrough, Hatch’s Legacy & Shanghai’s Lockdown

Long-awaited proof of concept for AstraZeneca’s PARP-1-selective therapy opens the door to combination strategies previously limited by hematopoietic toxicity, Senior Editor Karen Tkach Tuzman says on the latest edition of BioCentury This Week. Tkach Tuzman surveys data from the growing DNA damage repair (DDR) field from this year’s American Association for Cancer Research meeting, and the team also discusses the legacy of outgoing NCI Director Ned Sharpless, concerns over McKinsey's work for FDA and life sciences clients and the latest crop of BioCentury Emerging Company Profiles. This week’s podcast is sponsored by Bio€quity Europe.